Home › NDC Lookup › RxCUI directory › RxCUI 2739783

Zoliflodacin 3000 MG Granules for Oral Suspension — RxCUI 2739783

RxNorm drug concept · Semantic clinical drug
RxCUI 2739783 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2739783
Official nameZoliflodacin 3000 MG Granules for Oral Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known aszoliflodacin 3 GM Granules for Oral Suspension
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How Zoliflodacin 3000 MG Granules for Oral Suspensio... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Zoliflodacin 3000 MG Granules for Oral Suspension RxCUI 2739783

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Zoliflodacin 2734122
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Nuzolvence 2739784
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Zoliflodacin Granules for Oral Suspension 2739782
    • Zoliflodacin Granule Product 2739781
    • Zoliflodacin Oral Product 2739780
    • Zoliflodacin Granules for Oral Suspension [Nuzolvence] 2739788
    • Nuzolvence Granule Product 2739787
    • Nuzolvence Oral Product 2739786
    • Granules for Oral Suspension 1540454
    • Granule Product 1294708
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Zoliflodacin 3000 MG SCDC · 2739779
  • Zoliflodacin Granules for Oral Suspension SCDF · 2739782
  • Zoliflodacin Granule Product SCDG · 2739781
  • Zoliflodacin Oral Product SCDG · 2739780

Brand-Name Concepts

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2739783 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
68547-0915-10 1 PACKET in 1 CARTON (68547-915-10) / 1 FOR SUSPENSION in 1... NUZOLVENCE La Jolla Pharmaceutical Company 2026-04-01
Observed labelers: La Jolla Pharmaceutical Company (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.